WINDLAS Q1 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹210 Cr
verified against source
Revenue YoY
20%
reported change
EBITDA
₹27 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Windlas Biotech reported its 10th consecutive quarter of record revenue with 20% YoY revenue growth to ₹210 crore in Q1 FY26, outpacing the Indian pharma market's 9% growth. EBITDA rose 27% to ₹27 crore with margins expanding 70bps to 12.6%, driven by gross margin improvement of 71bps to 38.3%. PAT grew 31% to ₹18 crore with EPS of ₹8.4 (+30% YoY). All three verticals delivered healthy growth: CDMO (₹160 crore, +17.8%), Trade Generics (₹44 crore, +25.2%), and Exports (₹6 crore, +45.4%). The injectable facility is ramping up with improving utilization quarter-on-quarter, while Plant 6 refurbishment remains on track for phase-wise commercialization by late FY26 with ₹40-50 crore capex budgeted. Peak revenue potential is ₹1,100 crore (₹1,000 crore oral solids + ₹100 crore injectables) upon full capacity utilization. Risk: Injectable facility ramp-up remains slow; trade generics showed sequential softness; management declined to provide quantitative guidance or injectable utilization details.
Colored figures show movement against the previous available record.
Guidance to track
- Plant 6 refurbishment expected to complete in 2-3 quarters (by Q4 FY26), followed by validation phase. Phase-wise commercialization may yield some capacity in FY26, but full facility operational in FY27.
- Excluding injectables, ₹1,000 crore revenue potential upon Plant 6 capitalization; injectables add ₹100 crore, reaching ₹1,100 crore total. Potential upside through operational efficiencies.
- Phase 2 injectable capacity expansion (adding another floor) will only be triggered when facility approaches peak utilization (~₹100 crore run rate). Timeline: minimum 2 quarters from decision to operational.
- Management explicitly declined to provide medium-term (3-5 year) revenue growth targets, citing need to focus on execution rather than percentage commitments.
Risks flagged
- Management repeatedly deflected questions on injectable utilization levels and sequential revenue progression, citing competitive sensitivity. Last disclosed injectable revenue was 'not encouraging' in Q4 FY25. Quarter-on-quarter improvement was claimed but not quantified.
- Trade generics showed 25% YoY growth but 'lower' sequential growth vs Q4 FY25. Analyst questioned annual run rate target (₹200-225 crore); management attributed variation to tender timing and seasonal effects, advising annual rather than quarterly view.
- Analyst asked about wallet share improvement in CDMO business with Schedule M implementation driving migration from unorganized players. Management acknowledged inability to track wallet share due to lack of published data and customer confidentiality, only monitoring client concentration metrics.
- Analyst correctly noted that current depreciation run rate excludes Plant 6 impact. When Plant 6 is capitalized (expected late FY26), additional depreciation will begin, creating headwind to margins. Management confirmed 'extra depreciation starts kicking in' upon capitalization.
Key quotes
- Our business is more amenable to be evaluated on longer-term basis rather than quarter by quarter and also as a whole rather than part by part.
- We don't want to say that we are not giving guidance and then give guidance. The right thing is to look at our past performance in the last 10 quarters and our aspiration is always to better things.
- Injectable gross margins are higher... if you look at some pure injectable CDMO players, they are somewhere in the range of 18% to 21%. Potentially at least 10% of our revenue could be at 10-20% in that region once we execute.
Research modules